Trial Profile
An Assessment of the Biological and Clinical Effects of Palbociclib (PD 0332991) With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Patients With Premenopausal Estrogen-Receptor Positive/HER2-Negative Primary Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Apr 2022
Price :
$35
*
At a glance
- Drugs Goserelin (Primary) ; Letrozole (Primary) ; Palbociclib (Primary)
- Indications Early breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- 13 Apr 2022 Status changed from active, no longer recruiting to completed.
- 09 Sep 2020 Status changed from recruiting to active, no longer recruiting.
- 14 Dec 2019 Currently 12 of a planned 76 patients have been enrolled as per trial design presented at the 42nd Annual San Antonio Breast Cancer Symposium